The response of the body to a cancer is not a unique mechanism but has many parallels
with inflammation and wound healing. This article reviews the links between cancer and …

Most of oral targeted therapies are tyrosine kinase inhibitors (TKIs). Oral administration
generates a complex step in the pharmacokinetics (PK) of these drugs. Inter-individual PK …

Clinical studies with the Abl tyrosine kinase inhibitor STI-571 in chronic myeloid leukemia
demonstrate that many patients with advanced stage disease respond initially but then …

The interactive regulation between clock genes is central for oscillator function. Here, we
show interactions between the Arabidopsis clock genes LATE ELONGATED HYPOCOTYL …

Through sequencing analysis of blood or bone marrow samples from patients with chronic
myeloid leukemia, we identified BCR-ABL kinase domain mutations in 29 of 32 patients …

Imatinib has revolutionized drug therapy of chronic myeloid leukemia (CML). Preclinical
studies were promising but the results of clinical trials by far exceeded expectations …

This review discusses the development and uses of imatinib mesylate, a protein tyrosine
kinase inhibitor useful in the treatment of chronic myelogenous leukemia and …

Multidrug Resistance Proteins (MRPs), together with the cystic fibrosis conductance
regulator (CFTR/ABCC7) and the sulfonylurea receptors (SUR1/ABCC8 and SUR2/ABCC9) …

Most gastrointestinal stromal tumors (GIST) have an activating mutation in either KIT or
PDGFRA. Imatinib is a selective tyrosine kinase inhibitor and achieves a partial response or …

Blast crisis is the most advanced stage of chronic myelogenous leukemia (CML) and is
highly refractory to therapy. CML is caused by expression of the chimeric BCR-ABL tyrosine …